AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 10 240 GBX 1.05% Market Closed
Market Cap: 158.8B GBX
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one AZN stock under the Base Case scenario is 16 223.58 GBX. Compared to the current market price of 10 240 GBX, AstraZeneca PLC is Undervalued by 37%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZN Relative Value
Base Case
16 223.58 GBX
Undervaluation 37%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
95
vs Industry
29
Median 3Y
4.5
Median 5Y
4.6
Industry
2.4
Forward
0
More Details
27.2
P/E
P/E
Price to Earnings
27.2
vs History
88
vs Industry
13
Median 3Y
34.1
Median 5Y
37.5
Industry
20.5
Forward
0.1
More Details
16.1
P/OCF
P/OCF
Price to OCF
16.1
vs History
98
vs Industry
23
Median 3Y
20.7
Median 5Y
22.5
Industry
15.6
More Details
46.1
P/FCFE
P/FCFE
Price to FCFE
46.1
vs History
15
vs Industry
16
Median 3Y
40.4
Median 5Y
31.9
Industry
23.1
More Details
5.1
P/B
P/B
Price to Book Value
5.1
vs History
82
vs Industry
12
Median 3Y
5.4
Median 5Y
5.6
Industry
2
More Details
47.3
EV/S
EV/S
Enterprise Value to Sales
47.3
vs History
61
vs Industry
5
Median 3Y
49.1
Median 5Y
48.8
Industry
2.5
Forward
0.4
More Details
57.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
57.4
vs History
65
vs Industry
3
Median 3Y
60.2
Median 5Y
60.3
Industry
4.9
More Details
130.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
130.4
vs History
93
vs Industry
2
Median 3Y
153
Median 5Y
158.6
Industry
12.3
Forward
1.2
More Details
196.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
196.6
vs History
93
vs Industry
2
Median 3Y
252.5
Median 5Y
263.5
Industry
15.5
Forward
1.4
More Details
198.6
EV/OCF
EV/OCF
Enterprise Value to OCF
198.6
vs History
77
vs Industry
2
Median 3Y
239.5
Median 5Y
242.6
Industry
14.1
More Details
284.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
284.5
vs History
88
vs Industry
1
Median 3Y
347
Median 5Y
397.4
Industry
17.5
More Details
33.2
EV/IC
EV/IC
Enterprise Value to IC
33.2
vs History
36
vs Industry
3
Median 3Y
33.3
Median 5Y
30.6
Industry
1.8
More Details

Multiples Across Competitors

AZN Competitors Multiples
AstraZeneca PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
AstraZeneca PLC
LSE:AZN
158.8B GBP 3.8 27.2 130.4 196.6
US
Eli Lilly and Co
NYSE:LLY
696.2B USD 14.2 62.7 33.8 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
178.1B CHF 4 16.7 9.9 13.2
US
Merck & Co Inc
NYSE:MRK
191.1B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.5B EUR 1.3 9.2 5.1 5.9
US
Pfizer Inc
NYSE:PFE
126.7B USD 2 16.1 7 9.9
P/E Multiple
Earnings Growth PEG
UK
AstraZeneca PLC
LSE:AZN
Average P/E: 22.7
27.2
36%
0.8
US
Eli Lilly and Co
NYSE:LLY
62.7
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
US
Merck & Co Inc
NYSE:MRK
11
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
US
Pfizer Inc
NYSE:PFE
16.1
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
AstraZeneca PLC
LSE:AZN
Average EV/EBITDA: 394.2
130.4
9%
14.5
US
Eli Lilly and Co
NYSE:LLY
33.8
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
US
Pfizer Inc
NYSE:PFE
7
2%
3.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
AstraZeneca PLC
LSE:AZN
Average EV/EBIT: 1 697.5
196.6
21%
9.4
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4
US
Pfizer Inc
NYSE:PFE
9.9
10%
1

See Also

Summary
AZN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZN stock valuation using valuation multiples.
Wall Street Estimates
AZN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.